2009

1. Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety Results of a randomized, placebo-controlled study

   Arthritis and Rheumatism, Vol. 60, Núm. 4, pp. 976-986